Wave Life Sciences to Join RNA Therapeutics Panel
The company will discuss the trajectory of next-generation RNA medicine at a conference in New York City on October 20.
Updated on Oct. 13, 2026 in Biotech
Wave Life Sciences, a clinical-stage biotechnology firm, will participate in a panel regarding RNA therapeutics on October 20, 2026. This appearance will occur at the 10th Annual Chardan Healthcare Conference in New York City.
Why it matters
The panel serves as a forum for detailing the current development pipeline for RNA-based treatments. Such discussions are critical for tracking how clinical-stage companies shift from research into therapeutic application.
The firm operates as a clinical-stage entity, with the panel scheduled for 9:45 a.m. ET. This event marks the 10th iteration of the conference, which serves as a benchmark for investor and industry engagement with new biotech pipelines.
The players
Paul Bolno
President and Chief Executive Officer of Wave Life Sciences.
Wave Life Sciences
A clinical-stage biotechnology company focused on developing RNA-based therapeutic interventions.
The details
Wave Life Sciences focuses on RNA medicines, which utilize ribonucleic acid to modulate protein production in the body. The panel, titled RNA Medicines: Next-Generation RNA Therapeutics, will provide insights into the company's research methodology. Participants typically evaluate how these therapeutics can address genetic conditions that remain resistant to traditional small-molecule drugs.
Timeline
October 20, 2026, 9:45 a.m. ET marks the scheduled panel discussion.
The Tech Race
The conference functions as an annual bellwether for the competitive field of RNA-based drug discovery. Wave Life Sciences' participation tracks the company's standing relative to other clinical-stage firms navigating the transition from early research to human trials.
Observers can follow the panel via a live webcast provided on the company's investor portal at the scheduled time. This event offers the most direct opportunity for investors and industry analysts to review the company's current development milestones.
The takeaway
The panel offers a high-level view of how clinical-stage RNA developers are positioning their therapeutic pipelines for future impact. Watch for post-event disclosures or investor presentations on the company's website to confirm their current clinical trial trajectory.
What happens next
The panel is set for October 20, 2026, at 9:45 a.m. ET, with a live webcast to be hosted on the company's investor portal.
Further reading
Explore the latest developments in the field by visiting our Biotech section.
More information
View the live stream details on the Wave Life Sciences investor events portal.
